The IV Therapy Safety Revolution is seeing a significant advancement with a strategic distribution agreement between ivWatch, LLC, a leader in IV safety solutions, and Marathon Medical Corp. This partnership will make ivWatch’s advanced IV monitoring technology more accessible to various federal healthcare agencies in the U.S., including VA hospitals and Indian Health Service hospitals and clinics. This technology, which is backed by over 20 years of research and over 30 clinical studies, uses predictive algorithms and multi-spectral light to detect fluid leakage from veins in their earliest stages. The partnership also includes collaborative efforts in clinical vascular access education and product implementation support. This joint venture will greatly enhance patient safety, particularly for veterans, federal employees, and Native American communities.
Introduction
By Tim Ryan
Strategic Distribution Agreement
In a move that promises to enhance the safety of intravenous treatments across many federal healthcare agencies, ivWatch, LLC, a pioneer in IV safety solutions, has announced a significant distribution agreement with Marathon Medical Corp. This strategic alignment with Marathon Medical, a service-disabled veteran-owned small business renowned for its extensive medical product distribution, marks a pivotal step forward in the availability of advanced IV monitoring technology.
Enhanced Access to IV Monitoring Technology
Under the newly forged multi-year partnership, the ivWatch monitoring system will become more accessible to VA hospitals, Indian Health Service hospitals and clinics, and other Federal entities in the United States. The integration of ivWatch products into Marathon’s Federal Supply Schedule and GSA contracts stands to substantially elevate the products’ visibility and streamline access to this critical technology to improve IV therapy.
Advanced Technology and Clinical Support
ivWatch’s technology is grounded in over two decades of research and is backed by more than 30 clinical studies. Their devices utilize a combination of predictive algorithms and multi-spectral light to detect fluid leakage from veins at its earliest stage, preventing potential severe medical consequences. The partnership also encompasses collaborative efforts towards clinical vascular access education, facility product evaluations, and implementation support – a testament to their commitment to not only deliver cutting-edge technology but also ensure it integrates seamlessly into existing medical workflows.
Leadership and Shared Values
Gary Warren, the passionate president and CEO of ivWatch, brings a personal commitment to this partnership. As a former NASA federal employee with a family deeply ingrained in military service, including three sons who have served in the Navy, Warren sees this partnership as a reflection of shared patient safety values and a culture of empathy and selflessness.
Marathon Medical, led by Vietnam-era veteran John St. Leger since its inception in 2002, mirrors ivWatch’s dedication to patient care, honoring their service by supporting various veteran organizations. Their collaboration with ivWatch is a shared mission to bring safer IV treatment to veterans, federal employees, and Native American communities.
Future Impact and Innovation
As ivWatch and Marathon Medical unite in their quest to confront the silent epidemic of IV infiltration and extravasation, the healthcare landscape for federal patients is set to be transformed. For healthcare providers and patients interested in learning more about the technology that could redefine IV therapy’s safety standards, visit ivWatch’s technology overview.
Together, ivWatch and Marathon Medical are not only changing the narrative of patient safety but are also weaving their own stories of innovation and dedication into the larger fabric of healthcare. Stay tuned for this partnership’s impact on IV therapy outcomes and frontline clinical practices.
Question & Answer
What is the strategic distribution agreement between ivWatch, LLC and Marathon Medical Corp?
The strategic distribution agreement between ivWatch, LLC and Marathon Medical Corp aims to make ivWatch’s advanced IV monitoring technology more accessible to various federal healthcare agencies in the U.S., including VA hospitals, Indian Health Service hospitals, and clinics.
How does ivWatch’s technology work to enhance patient safety?
ivWatch’s technology uses predictive algorithms and multi-spectral light to detect fluid leakage from veins at its earliest stages, preventing potential severe medical consequences.
What is the significance of the partnership between ivWatch and Marathon Medical in terms of clinical support?
The partnership includes collaborative efforts towards clinical vascular access education, facility product evaluations, and implementation support to ensure the seamless integration of ivWatch’s technology into existing medical workflows.
What shared values and commitments do the leaders of ivWatch and Marathon Medical bring to this partnership?
Gary Warren, the president and CEO of ivWatch, and John St. Leger, the leader of Marathon Medical, both bring a personal commitment to patient safety and a shared mission to bring safer IV treatment to veterans, federal employees, and Native American communities.
